

DAFTAR PUSTAKA

- Aaronson, J. Essential Thrombocythemia. *Consults in Obstetric Anesthesiology* 2018, 191–192. https://doi.org/10.1007/978-3-319-59680-8_53.
- Alshammasi, B., Albasry, Z., & Meshikhes, F. (2020). Oral hyperpigmentation associated with hydroxyurea in a patient with polycythemia vera: A case report. *Clinical case reports*, 8(10), 1904–1909. <https://doi.org/10.1002/ccr3.3012>
- Arber, D. A.; Orazi, A.; Hasserjian, R. Errata: The 2016 Revision to the World Health Organization Classification of Myeloid Neoplasms and Acute Leukemia (Blood (2016) 127, 20 (2391–2405)). *Blood* 2016, 128, 462–463. <https://doi.org/10.1182/blood-2016-06-721662>.
- Barbui, T.; Thiele, J.; Gisslinger, H.; Kvasnicka, H.M.; Vannucchi, A.M.; Guglielmelli, P.; Orazi, A.; Tefferi, A. The 2016 WHO Classification and Diagnostic Criteria for Myeloproliferative Neoplasms: Document Summary and In-Depth Discussion. *Blood Cancer Journal* 2018, 8, 15. <https://doi.org/10.1038/s41408-018-0054-y>.
- Barbui, Tiziano et al. "Myeloproliferative neoplasms and thrombosis." *Blood* vol. 122,13 (2013): 2176-84. <https://doi.org/10.1182/blood-2013-03-460154>
- Baumeister, J.; Chatain, N.; Sofias, A.M.; Lammers, T.; Koschmieder, S. Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives. *Cells* 2021, 10, 3551. <https://doi.org/10.3390/cells10123551>.
- Boonyawat, K.; Wongwaisayawan, S.; Nitiyanant, P.; Atichartakarn, V. Hydroxyurea and Colonic Ulcers: A Case Report. *BMC Gastroenterol.* 2014, 14, 134. <https://doi.org/10.1186/1471-230X-14-134>.
- Cherdchoo, N.; Polprasert, C.; Rojnuckarin, P.; Kongkiatkamon, S. Clinical Characteristics and Symptom Burden of Thai Myeloproliferative Neoplasm Patients. *Hematology* 2023, 28(1), 2280731. <https://doi.org/10.1080/16078454.2023.2280731>.
- Eppingbroek, A.A.M.; Lechner, L.; Bakker, E.C.; Nijkamp, M.D.; de Witte, M.A.; Bolman, C.A.W. The Personal Impact of Living with a Myeloproliferative Neoplasm. *Psycho-Oncology* 2024, e6338. <https://doi.org/10.1002/pon.6338>.
- Fowlkes, S.; Murray, C.; Fulford, A.; De Gelder, T.; Siddiq, N. Myeloproliferative Neoplasms (MPNs) – Part 1: An Overview of the Diagnosis and Treatment of the "Classical" MPNs. *Can. Oncol. Nurs. J.* 2018, 28, 162-169. <https://doi.org/10.5737/23688076284262268>
- Ghasemi, A.; Keikhaei, B.; Ghodsi, R. Side Effects of Hydroxyurea in Patients with Thalassemia Major and Thalassemia Intermedia and Sick Cell Anemia. *Iranian Journal of Pediatric Hematology Oncology* 2018, 4(3).
- Ginzburg, Y. Z.; Feola, M.; Zimran, E.; Varkonyi, J.; Ganz, T.; Hoffman, R. Dysregulated Iron Metabolism in Polycythemia Vera: Etiology and Consequences. *Leukemia* 2018, 32, 2105–2116. <https://doi.org/10.1038/s41375-018-0207-9>.
- KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The inflammation-based neutrophil-lymphocyte ratio: experience in cancer. *Crit Rev Oncol Hematol.* 2013;88(1):218-30
- Wong, J.; Tan, E.J.; Foo, L.L.; Ong, K.H.; Lim, W.Y. Classic Myeloproliferative Neoplasms in Singapore: A Population-Based Study on Prevalence, and Survival from 1968 to 2017. *Cancer Epidemiology* 2022, 75. <https://doi.org/10.1016/j.canep.2022.102175>.



- Jayaraman, T.; Rajaram, R. B.; Gan, G. G.; Hilmi, I. Hydroxyurea associated ileocecal valve ulcer: evidence for causality. *Intest. Res.* 2021, 19, 468-471. <https://doi.org/10.5217/ir.2020.00099>.
- Jinna, S.; Khandhar, P. Hydroxyurea Toxicity. In [Title of Book]; [Publisher, if available]; Last Update: August 8, 2023. Available online: [https://www.ncbi.nlm.nih.gov/books/NBK537209/#_article-275_s6_] (accessed on [23 Desember 2024]).
- Kaifie, A.; Kirschner, M.; Wolf, D.; Maintz, C.; Hänel, M.; Gattermann, N.; Gökkurt, E.; Platzbecker, U.; Hollburg, W.; Göthert, J. R.; Parmentier, S.; Lang, F.; Hansen, R.; Isfort, S.; Schmitt, K.; Jost, E.; Serve, H.; Ehninger, G.; Berdel, W. E.; Brümmendorf, T. H.; Koschmieder, S.; for the Study Alliance Leukemia (SAL). Bleeding, Thrombosis, and Anticoagulation in Myeloproliferative Neoplasms (MPN): Analysis from the German SAL-MPN-Registry. *J. Hematol. Oncol.* 2016, 9, 18. <https://doi.org/10.1186/s13045-016-0242-9>.
- Karantanos, T.; Chaturvedi, S.; Braunstein, E.M.; Spivak, J.; Resar, L.; Karanika, S.; Williams, D.M.; Rogers, O.; Gocke, C.D.; Moliterno, A.R. Sex Determines the Presentation and Outcomes in MPN and Is Related to Sex-Specific Differences in the Mutational Burden. *Blood Adv.* 2020, 4, 1234–1244. <https://doi.org/10.1182/bloodadvances.2019001407>.
- Karantanos, T.; Gondek, L.P.; Varadhan, R.; Moliterno, A.R.; DeZern, A.E.; Jones, R.J.; Jain, T. Gender-Related Differences in the Outcomes and Genomic Landscape of Patients with Myelodysplastic Syndromes/Myeloproliferative Neoplasm Overlap Syndromes. *Br. J. Haematol.* 2021, 193, 1142–1150. <https://doi.org/10.1111/bjh.17534>.
- Khuahapinant, A.; Lertchaisataporn, K.; Phikulsod, P.; Siritanaratkul, N. Incidence and Characteristics of Polycythemia Vera, Essential Thrombocythemia and Primary Myelofibrosis in Thailand: A 5-Year Retrospective Study. *Blood* 2014, 124, 5563. <https://doi.org/10.1182/blood.V124.21.5563>.
- Kiladjian, J.-J.; Cassinat, B. Myeloproliferative Neoplasms and Splanchnic Vein Thrombosis: Contemporary Diagnostic and Therapeutic Strategies. *Am. J. Hematol.* 2023, 98, 211-218. <https://doi.org/10.1002/ajh.26896>.
- Kremyanskaya, M.; Najfeld, V.; Petersen, B.; Teruya-Feldstein, J. Myeloproliferative Neoplasms. *Atlas of Diagnostic Hematology* 2020, 52–81. <https://doi.org/10.1016/B978-0-323-56738-1.00005-1>.
- Kumar, B., Saraswat, A., & Kaur, I. (2002). Mucocutaneous adverse effects of hydroxyurea: A prospective study of 30 psoriasis patients. *Clinical and Experimental Dermatology*, 27(1), 8–13. <https://doi.org/10.1046/j.0307-6938.2001.00947.x>
- Maffioli, M.; Mora, B.; Passamonti, F. Polycythemia Vera: From New, Modified Diagnostic Criteria to New Therapeutic Approaches. *Clin. Adv. Hematol. Oncol.* 2017, 15, 700–707.



.; Eckert, R.; Huberty, J. Quality of Life in Myeloproliferative /mptoms and Management Implications. *Hematol. Oncol. Clin.* 15, 375–390. <https://doi.org/10.1016/j.hoc.2020.12.006>.

.; Zhou, L.; Liu, H. Combination Therapies in Chronic Myeloid Potential Treatment-Free Remission: Focus on Leukemia Stem

- Cells and Immune Modulation. *Front. Oncol.* 2021, 11, 643382. <https://doi.org/10.3389/fonc.2021.643382>.
- Nangalia, J.; Grinfeld, J.; Green, A.R. Pathogenesis of Myeloproliferative Disorders. *Annu. Rev. Pathol. Mech. Dis.* 2016, 11, 101–126. <https://doi.org/10.1146/annurev-pathol-012615-044454>.
- Rolles, B.; Mullally, A. Molecular Pathogenesis of Myeloproliferative Neoplasms. *Curr. Hematol. Malig. Rep.* 2022, 17, 319–329. <https://doi.org/10.1007/s11899-022-00685-1>.
- Shallis, R. M.; Wang, R.; Davidoff, A.; Ma, X.; Podoltsev, N. A.; Zeidan, A. M. Epidemiology of the Classical Myeloproliferative Neoplasms: The Four Corners of an Expansive and Complex Map. *Blood Rev.* 2020, 42, 100706. <https://doi.org/10.1016/j.blre.2020.100706>.
- Sobas, M.; Kiladjian, J.-J.; Beauverd, Y.; Curto-Garcia, N.; Sadjadian, P.; Shih, L.Y.; Devos, T.; Krochmalczyk, D.; Galli, S.; Bieniaszewska, M.; et al. Real-World Study of Children and Young Adults with Myeloproliferative Neoplasms: Identifying Risks and Unmet Needs. *Blood Adv.* 2022, 6, 3767–3779. <https://doi.org/10.1182/bloodadvances.2022007201>.
- Tefferi, A. 2022. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. *Blood*, 140(11), 1200–1228. <https://doi.org/10.1182/blood.2022015850>
- Tefferi, A.; Barbui, T. Polycythemia Vera and Essential Thrombocythemia: 2019 Update on Diagnosis, Risk-Stratification, and Management. *Am. J. Hematol.* 2019, 94, 133–143. <https://doi.org/10.1002/ajh.25303>.
- Tefferi, A.; Barbui, T. Polycythemia Vera and Essential Thrombocythemia: 2021 Update on Diagnosis, Risk-Stratification and Management. *Am. J. Hematol.* 2020, 95, 1599–1613. <https://doi.org/10.1002/ajh.26028>
- Tefferi, A.; Vannucchi, A. M.; Barbui, T. Polycythemia Vera: Historical Oversights, Diagnostic Details, and Therapeutic Views. *Leukemia* 2021, 35, 3339–3351. <https://doi.org/10.1038/s41375-021-01401-3>.
- Tefferi, Ayalew, and Tiziano Barbui. “Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.” *American journal of hematology* vol. 94,1 (2019): 133-143. doi:10.1002/ajh.25303
- Thapa, B.; Fazal, S.; Parsi, M.; Rogers, H.J. *Myeloproliferative Neoplasms*; StatPearls Publishing: Treasure Island, FL, USA, 2024.
- The Leukemia & Lymphoma Society. *Updated Data on Blood Cancers*. Leukemia & Lymphoma Society, 2023. Available online: https://www.lls.org/sites/default/files/2024-09/PS80_FactsBook_2024.pdf (accessed on 23 December 2024).
- Vidhatri, R. The Potential Underestimated Side Effect of Hydroxyurea. *J. Hematol. Allied Sci.* 2021, 2, 86–87. https://doi.org/10.25259/JHAS_16_2021



B. Advances in the Use of Hydroxyurea. *Hematology* 2009. ety of Hematology.

Sathar, J.; Lau, N.S.; Goh, A.S.; Chew, T.K.; Lim, S.M.; Menon, Husin, A.B.; Wong, L.L.L.; Chew, L.P.; Salleh, S.; Goh, K.Y.; an, S.M.; Ong, T.C.; Lim, S.H.; Toh, S.G.; Han, X.S.Y.; Edmund,

- S.C.; Tan, J.T.; Chang, K.M. The Epidemiology and Clinical Characteristics of Myeloproliferative Neoplasms in Malaysia. *Exp. Hematol. Oncol.* 2018, 7, 31. <https://doi.org/10.1186/s40164-018-0124-7>.
- Yarbro JW. Mechanism of action of hydroxyurea. *Semin Oncol.* 1992;19(3 Suppl 9):1-10.
- Yassin, M. A., Taher, A., Mathews, V., Hou, H. A., Shamsi, T., Tuğlular, T. F., Xiao, Z., Kim, S. J., Depei, W., Li, J., Rippin, G., Sadek, I., Siddiqui, A., & Wong, R. S. (2020). MERGE: A Multinational, Multicenter Observational Registry for Myeloproliferative Neoplasms in Asia, including Middle East, Turkey, and Algeria. *Cancer Medicine*, 9(13), 4512–4526. <https://doi.org/10.1002/cam4.3004>
- Yu, J.; Parasuraman, S.; Paranagama, D.; Bai, A.; Naim, A.; Dubinski, D.; Mesa, R. Impact of Myeloproliferative Neoplasms on Patients' Employment Status and Work Productivity in the United States: Results from the Living with MPNs Survey. *BMC Cancer* 2018, 18, 420. <https://doi.org/10.1186/s12885-018-4322-9>.
- Zalcberg, I.; Ayres-Silva, J.; de Azevedo, A.M.; Solza, C.; Dumas, A.; Bonamino, M. Hydroxyurea Dose Impacts Hematologic Parameters in Polycythemia Vera and Essential Thrombocythemia but Does Not Appreciably Affect JAK2-V617F Allele Burden. *Haematologica* 2011, 96, e20. <https://doi.org/10.3324/haematol.2010.037846>.
- Zargari, Omid et al. "Cutaneous adverse reactions to hydroxyurea in patients with intermediate thalassemia." *Pediatric dermatology* vol. 21,6 (2004): 633-5. <https://doi.org/10.1111/j.0736-8046.2004.21603.x>

